Next evidence
KSCBi019-A
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
StatusOpen
KSCBi019-A / CMC-hiPSC-009
Candidate placeholder. Claims require source verification before scoring.
Allele completeness: 0%
Allele-level HLA typing is missing, so population fit cannot be computed.
| Evidence Category | KSCBi019-ACMC-hiPSC-009 |
|---|---|
| Identity basic qc | |
| Cell viability | |
| STR authentication | |
| Mycoplasma PCRBlocker | |
| Microbial contaminationBlocker | |
| Viral contaminationBlocker | |
| Cell attachment / morphology | |
| Karyotype G-bandingBlocker | |
| Abnormal karyotype flagBlocker | |
| Pluripotency differentiation | |
| Pluripotency AP staining | |
| Pluripotency ICC | |
| Pluripotency qRT-PCR | |
| Differentiation EB formation | |
| Differentiation qRT-PCR | |
| Culture reprogramming | |
| Culture matrix | |
| Culture media | |
| Dissociation method | |
| Freezing media | |
| Source cell type | |
| Reprogramming method | |
| Feeder-free | |
| Xeno-free | |
| Hla population fit | |
| HLA typingBlocker | |
| HLA homozygous flag | |
| HLA population-fit score | |
| Genomics omics | |
| SNP / CNV | |
| WES or indel | |
| RNA-seq | |
| Methyl-seq | |
| STR profile detail | |
| Gmp regulatory commercial | |
| GMP documentationBlocker | |
| Formal CoABlocker | |
| Consent / commercial-use rightsBlocker | |
| Donor provenanceBlocker | |
| Distribution vial availability | |
| Clinical-grade supply status | |
| Exclusion flags | |
| Genetic modification statusBlocker | |
| Reporter line flagBlocker | |
| Disease-model flagBlocker | |
| Disease-related mutationBlocker | |
| Knockout / knock-in flagBlocker | |
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
Quality documentation
Obtain or review a formal CoA package.
Basic catalogue evidence is not a substitute for formal release documentation.
Quality documentation
Review GMP documentation and chain-of-custody package.
CMC planning needs GMP provenance before clinical development assumptions.
Genomic qc
Run or review SNP/CNV evidence.
Genome-wide copy-number evidence is missing or not reviewed.
Genomic qc
Review WES or indel evidence for candidate line risk.
Small variant evidence is needed before a stronger readiness claim.
Omics followup
Add RNA-seq evidence if program biology requires transcriptional comparison.
RNA-seq is useful for deeper comparability, but it is not the first blocker.
Omics followup
Add methylation evidence if epigenetic state is a program risk.
Methylation evidence can support later-stage comparability decisions.
| Priority | Line | Type | Recommendation | Rationale | Status |
|---|---|---|---|---|---|
| P1 | KSCBi019-A | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | KSCBi019-A | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
| P2 | KSCBi019-A | Quality documentation | Obtain or review a formal CoA package. | Basic catalogue evidence is not a substitute for formal release documentation. | Open |
| P2 | KSCBi019-A | Quality documentation | Review GMP documentation and chain-of-custody package. | CMC planning needs GMP provenance before clinical development assumptions. | Open |
| P3 | KSCBi019-A | Genomic qc | Run or review SNP/CNV evidence. | Genome-wide copy-number evidence is missing or not reviewed. | Open |
| P3 | KSCBi019-A | Genomic qc | Review WES or indel evidence for candidate line risk. | Small variant evidence is needed before a stronger readiness claim. | Open |
| P4 | KSCBi019-A | Omics followup | Add RNA-seq evidence if program biology requires transcriptional comparison. | RNA-seq is useful for deeper comparability, but it is not the first blocker. | Open |
| P4 | KSCBi019-A | Omics followup | Add methylation evidence if epigenetic state is a program risk. | Methylation evidence can support later-stage comparability decisions. | Open |